H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company announced results from its ReThink-ALZ Phase 3 trial with ...
H.C. Wainwright maintains a Buy rating and 12-month price target of $11 on CollPlant (CLGN) shares after the company reported Q3 results and ...
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage ...
H.C. Wainwright has recently initiated Quantum-Si Inc (QSI) stock to Buy rating, as announced on December 8, 2023, according to Finviz. Earlier, on September 25, 2023, Canaccord Genuity had reduced ...
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...
Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, saying that it anticipates a substantial drop in the company's kidney ...
On Tuesday, H.C. Wainwright maintained a Neutral rating for Mawson Infrastructure Group Inc. (NASDAQ: MIGI), following the company's recent production report. Mawson Infrastructure, transitioning ...
H.C. Wainwright adjusted the firm’s price target on Arqit Quantum (ARQQ) to $22 from $2 and keeps a Buy rating on the shares to reflect the ...
Phunware (NASDAQ:PHUN) shares retreated 11% in Tuesday late morning trading after H.C. Wainwright & Co. downgraded the application software company to Neutral from Buy, as analyst Scott Buck ...
On Thursday, H.C. Wainwright initiated coverage on Alumis Inc (NASDAQ: ALMS), a clinical-stage biopharmaceutical company, with a Buy rating and a 12-month price target of $30.00. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback